RxSight (RXST) vs Treace Medical Concepts (TMCI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Treace Medical Concepts (TMCI) has outperformed RxSight (RXST) over the past year, losing 37.1% versus a loss of 40.9%. Over five years, RXST leads with a -64.2% price change compared with -84.1% for TMCI. Treace Medical Concepts is the larger company by market cap ($252.0 million vs $201.7 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | RXST | TMCI |
|---|---|---|
| Share price | $4.85 | $3.88 |
| Market cap | $201.73M | $252.01M |
| 1-day change | +1.04% | -0.39% |
| YTD return | -53.45% | +58.16% |
| 1-year return | -40.93% | -37.09% |
| 5-year return | -64.23% | -84.13% |
| EPS (TTM) | $-1.14 | $-0.92 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $13.22 | $7.08 |
| 52-week low | $4.48 | $1.17 |
| Distance from 52-week high | -63.31% | -45.27% |
| Analyst consensus | none | none |
| Avg. price target upside | +56.08% | +41.94% |
| Average volume | 862.64K | 330.27K |
| Shares outstanding | 41.59M | 65.03M |
| Employees | 461 | 450 |
| Sector | Health Care | Health Care |
| Industry | Ophthalmic Goods | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About RxSight
RXST stock →RxSight, Inc., a commercial-stage medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.
Health Care · Ophthalmic Goods · 461 employees
About Treace Medical Concepts
TMCI stock →Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty System, enables surgeons to correct all three dimensions of the bunion deformity, stabilize the first TMT joint, and allow return to weight-bearing in a walking boot; minimally invasive products for four bunion classes; Nanoplasty 3D Minimally Invasive Bunion Correction System delivers a reproducible 3D correction of the bunion deformity through a cosmetically appealing; and Percuplasty Percutaneous 3D Bunion Correction System that provides 3D correction of the bunion deformity through percutaneous incisions.
Health Care · Medical/Dental Instruments · 450 employees
RXST vs TMCI FAQ
Which is bigger, RxSight or Treace Medical Concepts?
Treace Medical Concepts (TMCI) is larger, with a market capitalization of $252.01M compared with $201.73M for RxSight (RXST).
Which stock has performed better over the past year, RXST or TMCI?
TMCI returned -37.09% over the past 12 months, compared with -40.93% for RXST (price return, excluding dividends). Past performance does not predict future results.
Are RxSight and Treace Medical Concepts in the same industry?
Both are in the Health Care sector, but in different industries: Ophthalmic Goods for RxSight and Medical/Dental Instruments for Treace Medical Concepts.